Review synthesizes targeted therapies for pancreatic ductal adenocarcinoma, indicating ongoing improvements despite modest efficacy.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal digestive malignancies, with a 5-year survival rate <10%. Multimodal strategies are thus essential for improving prognosis. Recent advances in molecular biology and genomics have established targeted therapy as a pivotal approach to overcome limitations of conventional chemotherapy, stimulating extensive development of PDAC-targeted agents. This review synthesizes targeted therapeutics for PDAC reported between 2020 and 2025, analyzing literature from PubMed/MEDLINE, Scopus, and Cochrane Library. After systematic screening, 87 studies were categorized into 6 mechanistic classes. Although targeted agents demonstrate accelerated development, their clinical efficacy remains modest overall and typically requires chemotherapy combinations. Emerging research continues to elucidate PDAC pathogenesis, further refining targeted therapies with significant promise.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: